CRA, Momentum that I wont play:
CRA getting plenty of hype...Motley Fool added it...
Message 12320952
I'd post to the biotech overvalued fund, but have not
yet started that thread, and would be bad Karma.
I had read D.M. was about a large a genome as you
could expect to be sequenced by this shotgun method--
and too many repeat sequences in the human genome could
trip up Venter. I guess that is not a risk in the age
of "Gorilla" investing--you just have to look big and
important. Well, fine, let the stock go nuts, seems to
benefit the whole sector, if hype and momo spill all
over the place maybe I'll make a few peanuts too.
But would you hold it overnight? Imagine this possible headline
"Celera shotgun misses targets, makes monkey out of human DNA".
Obviously I'm not qualified to judge their method--the Fools
liked it because Celera means speed and Venter's company is fast,
so what? What makes the Motley Fool so special that they can
declare CRA a leader, seems awfully bold.
But there is money to be made.
After watching Tularik take off last week (still have not
found out why it was so sudden), maybe it would be
worth my time too look around for a few IPO's,
biowa's suggestion from awhile back seems as good
as any. I looked around to see if I could find
anything in the Seattle area, Rapigene was one that
turned up, private tho. Plenty of others I'm sure, but
who would put money on raw sequencing, besides the fools
and their followers of course.
Well, for now I feel pretty good about Genset, the
French GenHomme research funding, although a trifling
amount (150M U.S. dollars buys how many Big Macs in
Paris?) --but indicates to me that the Europeans want
to be in this, GENXY seems like a great way to diverisfy out
of U.S. genomics (not that I ever bought MLNM, HGSI, or
Incyte--but if I had, I'd diversify a bit.)
Let me pull out a few lines from Nature this past week:
"Five of the charter's six clauses concern confidentiality.
One says that annotated sequences cannot be submitted
to public databases before they have been subject to
intellectual property protection."
Just throwin this out there, it is going to be quite
a show. |
